Contact
searchSearch
HMP Global

Diffuse Large B-Cell Lymphoma News

News
Early, Late DLBCL Relapse Linked With Distinct Evolutionary Dynamics
08/17/2023
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have implications for clinical trial design and patient management, where early and late relapse patient populations should be considered separately and support additional molecular characterization of tumors at relapse to...
“These observations have...
08/17/2023
First Report Managed Care
News
Zanubrutinib Plus R-CHOP Effective for Non-GCB DLBCL With Extranodal Involvement
08/02/2023
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy and safety of a combination regimen that included zanubrutinib among treatment-naïve patients with non–germinal center B cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) with multiple extranodal...
Researchers studied the efficacy...
08/02/2023
First Report Managed Care
News
Study Finds Low Rate of CAR T-cell Therapy in Older Adults With DLBCL
07/27/2023
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was associated with favorable effectiveness, but the CAR T-cell therapy use in older patients was very low," particularly among patients aged at least 75 years, according to researchers.
"CAR T-cell therapy was...
07/27/2023
First Report Managed Care
News
CNS Prophylaxis Shows Limited Effectiveness in Preventing CNS Relapse in DLBCL
07/21/2023
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness, researchers also evaluated the financial toxicity and side effects associated with CNS prophylaxis for patients with diffuse large B-cell lymphoma. 
In addition to effectiveness,...
07/21/2023
First Report Managed Care
News
Prognosis Worse for Patients With DLBCL and Mental Health Disorders
07/20/2023
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse large B-cell lymphoma, pre-existing depression and anxiety were both associated with worse prognoses, according to recent findings.
Among patients with diffuse...
07/20/2023
First Report Managed Care
News
Epcoritamab Shows Durable Response in Relapsed/Refractory Large B-Cell Lymphoma
07/14/2023
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response rates with durability in patients with refractory large B-cell lymphoma treated with epcoritamab, including postchimeric antigen receptor-T therapy, represent further evidence of the value of bispecific antibodies...
“The observed high response...
07/14/2023
First Report Managed Care
News
Biosimilar Rituximab Compared to Originator Rituximab for Treatment of Patients With DLBCL
05/12/2023
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a phase 3 trial, biosimilar rituximab had comparable efficacy and safety to originator rituximab among patients with diffuse large B-cell lymphoma.
According to findings from a...
05/12/2023
Oncology
News
Anti-CD19 Monoclonal Antibodies for Treating Patients With R/R DLBCL
05/20/2022
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed loncastuximab tesirine and tafasitamab for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Researchers reviewed...
05/20/2022
First Report Managed Care
News
Loncastuximab Tesirine Efficacious, Safe for Patients With R/R DLBCL
05/13/2022
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the efficacy of loncastuximab tesirine in treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Study authors assessed the...
05/13/2022
First Report Managed Care
News
HRQoL Maintained or Improved With Treatment for Patients With R/R DLBCL
04/25/2022
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate already shown to have antitumor activity and manageable toxicity also improved health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma, according to new findings. 
An antibody-drug conjugate...
04/25/2022
First Report Managed Care
FRMC Volume 21, Issue 4

Current Issue

October/November/December Volume 21, Issue 4, First Report Managed Care
Current Issue
Issue Archive

What's Trending?

Analysis of 2015 Premiums as the Second Year of Marketplace Open Enrollment Approaches
11/03/2014
With open enrollment right around the corner, a report from the Kaiser Family Foundation examined changes in coverage under the Patient Protection and Affordable Care Act (ACA) moving into 2015.
With open enrollment right around the corner, a report from the Kaiser Family Foundation examined changes in coverage under the Patient Protection and Affordable Care Act (ACA) moving into 2015.
With open enrollment right...
11/03/2014
First Report Managed Care
News
Massachusetts Sues J&J Over Risperdal Marketing Practices
08/04/2011
08/04/2011
First Report Managed Care
News
FDA Approves Drug for Schizoaffective Disorder
11/15/2014
The FDA approved paliperidone palmitate, an atypical long-active antipsychotic, manufactured by Janssen Pharmaceuticals, Inc, for the treatment of schizoaffective disorder.
The FDA approved paliperidone palmitate, an atypical long-active antipsychotic, manufactured by Janssen Pharmaceuticals, Inc, for the treatment of schizoaffective disorder.
The FDA approved paliperidone...
11/15/2014
First Report Managed Care
News
Patient Assistance Program Improves Outcomes for Low-Income RA Patients
11/07/2017
According to research at the ACR/ARHP 2017 Annual Meeting, a patient assistance program and dedicated health care team within a community clinic setting can benefit low-income patients with accessing treatment and high cost biologics.
According to research at the ACR/ARHP 2017 Annual Meeting, a patient assistance program and dedicated health care team within a community clinic setting can benefit low-income patients with accessing treatment and high cost biologics.
According to research at the...
11/07/2017
First Report Managed Care
News
Insurance Industry`s Final Ad Blitz: Don`t Blame Us For Your High Costs
03/09/2010
03/09/2010
First Report Managed Care

Video Insights

Formoso Headshot
Videos
Minimally Invasive Solutions for Lumbar Disc Herniation
01/07/2025
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Ferdinand Formoso, DO, discusses the role of condoliase as a minimally invasive treatment for lumbar disc herniation, its safety profile, potential areas for further research, and its ability to address unmet needs in spine...
In this interview, Ferdinand...
01/07/2025
First Report Managed Care
Kolodziej Headshot
Videos
Navigating Biosimilar Adoption: Lessons from Global Markets and Clinical Practices
12/20/2024
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael Kolodziej, MD, discusses strategies for enhancing biosimilar adoption in the US, emphasizing lessons from global markets, the importance of payer flexibility, and the need for collaboration to reduce costs and...
In this interview, Michael...
12/20/2024
First Report Managed Care
Mike Kolodziej, MD
Videos
Exploring Biosimilar Adoption and Policy Impacts in Oncology
12/18/2024
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
In this interview, Michael Kolodziej, MD, discusses the role of biosimilars in value-based care models, their relationship with targeted therapies, and the impact of policy changes and market trends on biosimilar adoption and cost...
In this interview, Michael...
12/18/2024
First Report Managed Care
Hennessy Headshot
Videos
Navigating Biosimilar Integration: Cost Savings, Coverage, and Future Strategies for Payers
12/10/2024
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
John Hennessy, MBA, discusses the complexities of biosimilar adoption, highlighting potential cost savings, payer strategies, challenges in provider and patient acceptance, regulatory impacts, and the critical need for sustainable market...
John Hennessy, MBA, discusses...
12/10/2024
First Report Managed Care
Videos
Bridging the Gaps in Prior Authorization: Challenges, Solutions, and Collaboration for Better Patient Care
11/13/2024
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief...
11/13/2024
First Report Managed Care
Richard Lipton, MD
Videos
The Evolving Role of CGRP-targeting Therapies in Migraine Prevention
10/31/2024
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides...
10/31/2024
First Report Managed Care
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
First Report Managed Care
Videos
Treatment Options for NSCLC: A Discussion on Coverage, Clinical Outcomes, and Payer Perspectives
09/25/2024
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research...
09/25/2024
First Report Managed Care
Title Card
Videos
Addressing the Root Cause of a Common Ocular Condition: A Virtual Roundtable
09/04/2024
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on Demodex blepharitis, a prevalent ocular condition that often goes undiagnosed in patients.
View a roundtable discussion on...
09/04/2024
First Report Managed Care
Jordan Bazinsky
Videos
Addressing Health Disparities and Promoting Equity: The Role of Advanced Imaging Solutions
08/15/2024
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky...
08/15/2024
First Report Managed Care

Subscribe to our eNewsletters!

First Report Managed Care Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use